Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur irrespective of race. Old age and long-term use of corticosteroid may be a more reliable risk factor than racial characteristics. Introduction: BRONJ is an increasingly common problem. Most BRONJ occurs following an intravenous administration of bisphosphonate treatment for malignant bone disease and metastatic cancer. As the incidence of BRONJ caused by oral administration of bisphosphonate is quite low, it is believed that this medication is relatively safe and effective in preventing complications of osteoporosis, such as hip or spine fractures. The many known risk factors for BRONJ can be classified as drug-related, local, demographic, and systemic. One demographic and systemic risk factor is race. Most of the case reports of BRONJ present elderly, white women. Methods: In this report, we describe five cases of BRONJ caused by oral administration of bisphosphonate in Asian population. Results: All the patients were female and over 65 years old. Three patients had been prescribed with corticosteroids for rheumatoid arthritis. Conclusion: Irrespective of race, elderly women undergoing steroid therapy have an increased incidence of BRONJ even with oral administration of bisphosphonate.
Bibliographical noteFunding Information:
This work was supported by the Korea Science and Engineering Foundation (KOSEF) with a grant funded by the Korea government (MEST; no. R01-2008-000-21000-0).
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism